Home › Research › Biomarkers
Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia
Ingannato A, Bagnoli S, Mazzeo S, Giacomucci G, Bessi V, Ferrari C, Sorbi S, Nacmias B.. Frontiers in endocrinology, 2024-04-09
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Background Plasma biomarkers are preferable to invasive and expensive diagnostic tools, such as neuroimaging and lumbar puncture that are gold standard in the clinical management of Alzheimer's Disease (AD). Here, we investigated plasma Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL) and Phosphorylated-tau-181 (pTau 181) in AD and in its early stages: Subjective cognitive decline (SCD) and Mild cognitive impairment (MCI). Material and methods This study included 152 patients (42 SCD, 74 MCI and 36 AD). All patients underwent comprehensive clinical and neurological assessment. Blood samples were collected for Apolipoprotein E (APOE) genotyping and plasma biomarker (GFAP, NfL, and pTau 181) measurements. Forty-three patients (7 SCD, 27 MCI, and 9 AD) underwent a follow-up (FU) visit after 2 years, and a second plasma sample was collected. Plasma biomarker levels were detected using the Simoa SR-X technology (Quanterix Corp.). Statistical analysis was performed using SPSS software version 28 (IBM SPSS Statistics). Statistical significance was set at p < 0.05. Results GFAP, NfL and pTau 181 levels in plasma were lower in SCD and MCI than in AD patients. In particular, plasma GFAP levels were statistically significant different between SCD and AD ( p =0.003), and between MCI and AD ( p =0.032). Plasma NfL was different in SCD vs MCI ( p =0.026), SCD vs AD ( p <0.001), SCD vs AD FU ( p <0.001), SCD FU vs AD ( p=0.033 ), SCD FU vs AD FU ( p=0.011 ), MCI vs AD ( p =0.002), MCI FU vs AD ( p =0.003), MCI FU vs AD FU ( p =0.003) and MCI vs AD FU ( p =0.003). Plasma pTau 181 concentration was significantly different between SCD and AD ( p =0.001), MCI and AD ( p =0.026), MCI FU and AD ( p =0.020). In APOE ϵ4 carriers, a statistically significant increase in plasma NfL ( p<0.001 ) and pTau 181 levels was found ( p=0.014). Moreover, an association emerged between age at disease onset and plasma GFAP (p = 0.021) and pTau181 (p < 0.001) levels. Discussion and conclusions Plasma GFAP, NfL and pTau 181 are promising biomarkers in the diagnosis of the prodromic stages and prognosis of dementia.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ingannato, A., Bagnoli, S., Mazzeo, S., Giacomucci, G., Bessi, V., Ferrari, C., et al. (2024). Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2024.1375302
Vancouver
Ingannato A, Bagnoli S, Mazzeo S, Giacomucci G, Bessi V, Ferrari C, et al. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia. Frontiers in endocrinology. 2024. doi:10.3389/fendo.2024.1375302. PMID: 38654932.
BibTeX
@article{ingannato2024-38654932,
author = {Ingannato, A. and Bagnoli, S. and Mazzeo, S. and Giacomucci, G. and Bessi, V. and Ferrari, C. and Sorbi, S. and Nacmias, B.},
title = {{Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia}},
journal = {Frontiers in endocrinology},
year = {2024},
doi = {10.3389/fendo.2024.1375302},
pmid = {38654932},
url = {https://doi.org/10.3389/fendo.2024.1375302}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Results GFAP, NfL and pTau 181 levels in plasma were lower in SCD and MCI than in AD patients.
- In particular, plasma GFAP levels were statistically significant different between SCD and AD ( p =0.003), and between MCI and AD ( p =0.032).
- Plasma pTau 181 concentration was significantly different between SCD and AD ( p =0.001), MCI and AD ( p =0.026), MCI FU and AD ( p =0.020).
- In APOE ϵ4 carriers, a statistically significant increase in plasma NfL ( p<0.001 ) and pTau 181 levels was found ( p=0.014).
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants152
- Evidence strengthLow
How this study scored 53/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 31 of the 58 points we could judge it on, which is 53 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in endocrinology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 152 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38654932) |
| Free to read | 2 / 2 | Free to read |
| Points | 31 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 31 of the 58 points we could judge it on is 53 out of 100. |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.